View Exam | PowerPak

1. Approximately what proportion of lung adenocarcinomas harbor drug-targetable mutations?

A. 14% B. 34% C. 64% D. 84%

2. Which of the following statements regarding epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is MOST accurate?

A. The EGFR tyrosine kinase inhibitors (TKIs) improve overall survival in patients with NSCLC. B. The 3 options for first-line therapy are afatinib, erlotinib, and gefitini C. The EGFR exon 19 del mutation predicts worse response to EGFR TKI therapy. D. Approximately 30% of patients will develop resistance to EGFR TKIs after 9 to 12 months of treatment.

3. BK is a 68-year-old woman with ALK-rearranged non-small cell lung cancer. She responded well to first-line treatment with crizotinib monotherapy but relapsed after 9 months of therapy. Which of the following describes the MOST APPROPRIATE next steps for treatment?

A. Retreat her with crizotinib. B. Treat her with pemetrexed-based chemotherapy. C. Treat her with ceritinib or alectinib. D. Treat her with osimertinib.

4. MP is a 70-year-old man with EGFR-mutated non-small cell lung cancer. He responded well to first-line treatment with erlotinib monotherapy but relapsed after 14 months of therapy. His physician ordered a repeat biopsy, which identified the presence of the EGFR T790M mutation. Which of the following describes the MOST APPROPRIATE treatment?

A. Gefitinib B. Afatinib C. Osimertinib D. Pemetrexed

5. Which of the following statements regarding the financial toxicity of targeted cancer treatment is MOST ACCURATE?

A. Financial toxicity has little correlation with medication adherence. B. Approximately 1 in 3 insured cancer patients will experience significant debt or bankruptcy. C. An influx of new targeted therapies from the oncology pipeline is expected to relieve the financial toxicity of non-small cell lung cancer treatment. D. Patients demonstrate better adherence to oral targeted therapies due to lower out-of-pocket costs.

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Approximately what proportion of lung adenocarcinomas harbor drug-targetable mutations?

2. Which of the following statements regarding epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is MOST accurate?

3. BK is a 68-year-old woman with ALK-rearranged non-small cell lung cancer. She responded well to first-line treatment with crizotinib monotherapy but relapsed after 9 months of therapy. Which of the following describes the MOST APPROPRIATE next steps for treatment?

5. Which of the following statements regarding the financial toxicity of targeted cancer treatment is MOST ACCURATE?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Approximately what proportion of lung adenocarcinomas harbor drug-targetable mutations?

2. Which of the following statements regarding epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is MOST accurate?

3. BK is a 68-year-old woman with ALK-rearranged non-small cell lung cancer. She responded well to first-line treatment with crizotinib monotherapy but relapsed after 9 months of therapy. Which of the following describes the MOST APPROPRIATE next steps for treatment?

5. Which of the following statements regarding the financial toxicity of targeted cancer treatment is MOST ACCURATE?

« Return to Activity

Customers who Purchased
this Activity also Purchased